Biotech Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Angiotensin

AT₁ -Mas complex could be target for intervention in CV diseases

According to scientists in Netherlands, "We previously identified the G-protein-coupled receptor Mas, encoded by the Mas proto-oncogene, as an endogenous receptor for the heptapeptide angiotensin-(1-7); however, the receptor is also suggested to be involved in actions of angiotensin II. We therefore tested whether this could be mediated indirectly through an interaction with the angiotensin II type 1 receptor, AT₁ ."

E. Kostenis and colleagues of 7TM Pharma explained, "In transfected mammalian cells, Mas was not activated by angiotensin...

• View Other Issues of Biotech Business Week
  
• View Other NewsRx Publications